Germline mutations of the gene encoding human ®broblast growth factor receptor 3 (FGFR3) have been shown to be responsible for several related autosomal dominant forms of syndromic craniosynostosis and short limb dwar®sm. Somatic activating mutations of FGFR3 were recently reported to occur in three of 12 (25%) uterine cervical carcinomas and nine of 26 (35%) bladder carcinomas, suggesting that constitutive activation of FGFR3 may be an important mechanism underlying the development and/or progression of these common epithelial malignancies. In order to investigate further a possible role for FGFR3 mutations in cervical carcinogenesis, we performed sequence-based mutational analysis of FGFR3 in 51 primary cervical carcinomas and seven cervical carcinoma-derived cell lines. The regions analysed (exons 7, 10, 13, 15, and 19) encompassed all previously described FGFR3 mutations. A single nucleotide substitution at codon 249, predicting a serine to cysteine amino acid substitution (S249C) in the FGFR3 extracellular domain, was identi®ed in one primary tumor. Only wild type FGFR3 alleles were identi®ed in the remaining tumors and cell lines. The S249C mutation is the only FGFR3 mutation described to date in cervical carcinomas. These ®ndings suggest that while activating mutations of FGFR3 occur in cervical cancer, they may not be as common as initially reported. Oncogene (2000) 19, 5543 ± 5546.
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Keywords: cervical cancer; FGFR; oncogene Cervical cancer remains a major national and world health problem. Although infection with certain (`highrisk') types of human papillomaviruses (HPVs) is now considered a necessary cause of cervical cancer (Walboomers et al., 1999) , it is certainly not sucient. In fact, a number of observations suggest that cofactors in¯uence the development of cervical cancer in addition to HPV. Among these cofactors, somatic mutations in oncogenes and tumor suppressor genes are likely. The speci®c oncogenes commonly activated during cervical carcinogenesis remain incompletely de®ned, but include c-MYC (Baker et al., 1988; Riou et al., 1990) , RAS (Riou et al., 1988; Wong et al., 1995; Grendys et al., 1997) , HER2/NEU (Mitra et al., 1994) , and EGFR (Kersemaekers et al., 1999) .
The FGFR3 gene on chromosome 4p16.3 encodes one of four highly conserved and closely related cell membrane-associated receptors (FGFR1 ± 4) that play important roles in the cell signaling pathways regulating embryonic growth, development, cell proliferation, dierentiation, and angiogenesis (Johnson and Williams, 1993) . Activation of signaling requires interactions between growth factor, receptor, and heparan sulfate proteoglycans. The FGFR proteins are characterized by an extracellular domain with three glycosylated immunoglobulin-like domains (I ± III), a transmembrane domain, and a split intracellular tyrosine kinase domain. The FGFR3 gene consists of 19 exons and 18 introns spanning 16.5 kb (PerezCastro et al., 1997; WuÈ chner et al., 1997) . Activating mutations in speci®c domains of FGFR3 have been shown to be responsible for a number of autosomal dominant craniosynostotic conditions and skeletal dysplasias such as thanatophoric dysplasia (TD), achondroplasia, hypochondroplasia, severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), and platyspondylic lethal skeletal dysplasia (PLSD) [reviewed in (Passos-Bueno et al., 1999) ]. The phenotype-genotype correlations within this group of disorders are complex, as clinically dierent syndromes can be due to the same mutation, and given clinical syndromes can be due to a number of dierent mutations in the same or dierent FGFR3 genes.
In 1997, two independent groups provided data supporting a role for FGFR3 activation in human cancer (Chesi et al., 1997; Richelda et al., 1997) . Chromosomal translocations t(4;14)(p16.3;q32.3) resulting in deregulated expression of FGFR3, as well as point mutations activating FGFR3, were demonstrated in a subset of multiple myelomas. More recently, Cappellen et al. (1999) provided the ®rst evidence of a role for FGFR3 activation in epithelial malignancies, reporting mutations of FGFR3 in 25 and 35% of cervical and bladder carcinomas, respectively. Although their ®ndings suggest that FGFR3 may be an important target for activation in cervical tumorigenesis, only 12 cervical carcinomas were evaluated.
We analysed a larger number of cervical carcinomas (51 primary tumors and seven carcinoma-derived cell lines) for FGFR3 mutations in an attempt to de®ne further a role for FGFR3 activation in cervical tumorigenesis. The 51 primary cervical carcinomas available for evaluation represent a subset of tumors from two epidemiological studies of cervical cancer. Thirty-one tumors were collected from 1985 to 1988 as part of a population-based case-control study of cervical cancer in Colombia and Spain, the former country having an incidence of cervical cancer approximately eight times higher than the latter Bosch et al., 1992) . Twenty additional carcinomas were collected from 1991 to 1993 as part of a case-control study of cervical cancer in the Philippines (Ngelangel et al., 1998) . All samples were frozen immediately after removal and stored at 7708C until use. Of the 51 tumors, 50 were squamous carcinomas and one was an adenosquamous carcinoma. All primary cervical carcinomas were microdissected prior to DNA extraction, such that DNA was extracted from samples composed of at least 80% tumor cells. DNA was also extracted from matched non-neoplastic tissue obtained from each patient whose tumor showed sequence alterations of FGFR3. Nonneoplastic cells were isolated from frozen tissues by either manual microdissection, or when necessary, by laser capture microdissection (LCM), in order to ensure virtual absence of contaminating tumor cells. The seven cervical carcinoma-derived cell lines evaluated (C-33A, C-4II, HeLa, SiHa, CaSki, HT3, and ME-180) were obtained from the American Type Culture Collection. Regions of the gene encompassing all previously described FGFR3 mutations (exons 7, 10, 13, 15, and 19 and adjacent intron sequences) were initially evaluated by direct sequencing of PCRampli®ed genomic DNA using the primers listed in Table 1 .
A missense mutation in exon 7 was identi®ed in one primary tumor, a FIGO Stage IIB squamous carcinoma from a 53 year old Spanish woman (Figure 1 ). The single nucleotide substitution was a G ? C transversion at the second position of codon 249 (nucleotide 746), predicting a Ser ? Cys amino acid substitution (S249C) in the extracellular domain of FGFR3. The somatic nature of the mutation was con®rmed by demonstration of only wild type alleles in nonneoplastic cells from the same patient. The other 50 primary cervical carcinomas and all seven carcinomaderived cell lines contained only wild type FGFR3 alleles. Two silent sequence polymorphisms within FGFR3 were also identi®ed. A C ? T substitution at the third position of codon 294 in exon 7 was demonstrated in one or both alleles of 49 primary tumors and in all seven cell lines. An A ? G substitution at the third position of codon 651 in exon 15 was identi®ed in one FGFR3 allele of three primary tumors. No sequence alterations of FGFR3 were found in exons 10, 13, or 19.
Given that the S249C mutation is the only FGFR3 mutation described to date in cervical carcinomas, we employed a second method of mutation detection to con®rm the low frequency of this mutation in our set of primary tumors. Exon 7 PCR products from each tumor were hybridized to radiolabeled oligonucleotides speci®c for the S249C mutation or for the wild type sequence (Figure 2 ). This method is capable of detecting even small percentages of tumor cells harboring the mutation. Again, the S249C mutation was identi®ed only in sample 24T, and not in the remaining 50 primary tumors or seven cell lines.
To determine whether FGFR3 might be activated in cervical carcinomas due to overexpression of wild type sequences, FGFR3 transcripts were evaluated by Northern blot analysis in all seven cervical carcinoma-derived cell lines and in primary foreskin and cervical keratinocytes (Figure 3) . ME-180 carcinoma cells showed a level of FGFR3 expression comparable to that seen in normal keratinocytes. The remaining cell lines showed reduced or undetectable FGFR3 mRNA expression.
Germline mutations of the gene encoding FGFR3 are responsible for several related autosomal dominant forms of syndromic craniosynostosis and short limb dwar®sm (Passos-Bueno et al., 1999). Many of the reported mutations convert existing amino acids to Figure 1 S249C (exon 7) mutation of FGFR3 mutation in primary cervical carcinoma 24T. The arrowhead indicates the point mutation (TCC ? TGC) in tumor DNA. The corresponding sequence in DNA from matched normal tissue (24N) is wild type. Puri®ed PCR products were sequenced using the ThermoSequenase Radiolabeled Terminator Cycle sequencing kit (USB, Cleveland OH, USA) with either forward and/or reverse primers noted in Table 1 . Exons 7 and 15 were also sequenced using additional internal primers (exon 7: 5'-GGTGAGGGAGGGGG-TGG-3''; exon 15: 5'-CCCTGCCTCCCACCCCTT-3') FGFR3 mutations are uncommon in cervical carcinomas R Wu et al cysteine residues in the extracellular domain of FGFR3. These cysteine-generating alterations have been identi®ed at multiple sites in the FGFR3 extracellular domain. For example, the R248C and S249C mutations aect the region between the second and third immunoglobulin-like domains, while the G370C, S371C, Y373C and G375C substitutions aect the region between the third immunoglobulin-like domain and the transmembrane domain (Ikegawa et al., 1995; Tavormina et al., 1995; Rousseau et al., 1996; Naski et al., 1996; Katsumata et al., 1998) . These mutations create unpaired cysteine residues that result in the formation of inappropriate intramolecular or intermolecular disul®de bonds between the extracellular domains of mutant FGFR3 monomers, with ligandindependent dimerization and constitutive activation of the receptor complex (d'Avis et al., 1998) . In further support of this hypothesis, Chen et al. (1999) have shown that a glycine-to-cysteine substitution at codon 375 (G375C) in human FGFR3 causes ligand-independent dimerization and phosphorylation of FGFR3.
The equivalent substitution at codon 369 (G369C) in mouse FGFR3 causes dwar®sm with features mimicking human achondroplasia (Chen et al., 1999) . The role of FGFR3 activation in human cancer is only beginning to be elucidated. In as many as 25% of multiple myelomas, the FGFR3 gene at 4p16.3 is translocated to chromosome 14q32 as a result of a karyotypically undetectable chromosomal translocation t(4;14)(p16.3;q32) (Chesi et al., 1997; Richelda et al., 1997; Fracchiolla et al., 1998; Finelli et al., 1999) . This translocation is associated with deregulated expression of FGFR3, which presumably results in inappropriate signaling supporting the growth and/or survival of malignant plasma cells. Several of the FGFR3 mutations associated with inherited skeletal disorders have also been detected as somatic mutations in myeloma cell lines and primary tumors carrying the t(4;14)(p16.3;q32) translocation (Chesi et al., 1997; Richelda et al., 1997) . The translocation also results in deregulated expression of a novel gene on chromosome 14, MMSET, which is also thought to contribute to neoplastic transformation (Chesi et al., 1998; Stec et al., 1998) .
More recently, Cappellen and colleagues provided evidence supporting an oncogenic role for FGFR3 in human bladder and cervical carcinomas (Cappellen et al., 1999) . All of the somatic mutations identi®ed (R248C, S249C, G370C and K650E) were identical to previously reported germline mutations associated with thanatophoric dysplasia. We identi®ed one primary tumor with the same S249C mutation observed by Cappellen et al. (1999) in three cervical cancers harboring somatic mutations of FGFR3. However, our data suggest that FGFR3 mutations are signi®cantly less common in cervical carcinomas than initially suggested [1/58 (1.7%) versus 3/12 (25%)]. An alternative explanation for the varying frequencies of FGFR3 mutations is that mutations of the gene may be more prevalent in cervical carcinomas of speci®c ethnic populations, given that our primary tumor specimens were from women in the Philippines, Spain and Colombia. Cappelen and colleagues did not specify the ethnicity of women whose tumors were studied in their series.
Donoghue and colleagues have reported that the full length S249C FGFR3 mutant is inactive in NIH3T3 transformation assays (d'Avis et al., 1998) , and we have con®rmed lack of transforming activity of the full length S249C mutant in two rodent cell lines (NIH3T3 (murine ®broblast) and RK3E (E1A immortalized rat epithelial)), and two human papillomavirus immortalized keratinocyte cell lines, 8217 (Kessis et al., 1993) and 1811 (Hurlin et al., 1991 ) (Cho laboratory, unpublished studies). However, a chimeric receptor containing the extracellular domain of mutant FGFR3 (S249C or R248C) fused to the transmembrane and intracellular domains of Neu, results in morphological transformation that is not observed with comparable constructs using the extracellular domain of wild type FGFR3 or a control mutant (R248A) (d'Avis et al., 1998) .
Collectively, the molecular genetic and functional data support a role for FGFR3 activation in some types of human cancers, including those of the uterine cervix. However, the prevalence of mutations in cervical carcinomas is likely to be signi®cantly lower than suggested by earlier studies.
Abbreviations FGFR3, ®broblast growth factor receptor 3; FGF, ®bro-blast growth factor; HPV, human papillomavirus; PCR, polymerase chain reaction; MM, multiple myeloma; TD, thanatophoric dysplasia. Based on comparison to the migration of RNA standards of known size, the FGFR3 mRNAs were estimated to be approximately 4.4 kb. To control for potential loading dierences between samples, the blot was co-hybridized to a control probe for GAPDH Figure 2 Hybridization of S249C mutation-speci®c and wild type oligonucleotides to FGFR3 exon 7 PCR products from representative primary tumors. Exon 7 PCR products (299 bp) were resolved on 1% agarose gels, then transferred to Zeta-probe GT nylon membranes (Bio-Rad, Hercules, CA, USA). The blots were hybridized to S249C mutation-speci®c (CTGGAGCGCTG-CCCGCACCG) or wild type (CTGGAGCGCTCCCCGCACCG) oligonucleotides end-labeled with g-32 P-ATP (Amersham, Arlington Heights, IL, USA) and puri®ed using G-25 columns (Boerhringer Mannheim, Indianapolis, IN, USA). Following hybridization in Rapid Hyb buer (Amersham) at 678C for 4 h, blots were washed and autoradiography was performed. Speci®-city of the mutant and wild type probes was con®rmed by hybridization of each probe to plasmid DNA containing the S249C mutant or wild type FGFR3 sequences (gift from Dr Dan Donoghue, University of California at San Diego, USA)
